English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of this review article is to make readers aware of the risk of an inadequate antiplatelet effect of enteric-coated formulations of aspirin. Judging by data from studies published to date and exploring the efficacy of various aspirin formulations, there exist sufficient evidences only of a plain form of aspirin absorbed in the stomach. The implication is that patients with coronary heart disease (CHD) should be treated exclusively with the standard formulation of aspirin.

Enteric-coated aspirin in cardiac patients: Is it less effective than plain aspirin?